[U.S.] May 2024, In re Bystolic (Second Circuit Court of Appeals)
Updated: 6 hours ago
Article information
Article type: Case note
Category: United States
Topics: —
First published on this website: 2026-11-01
Display and classification checked: November 2, 2026
Originally published on Ameblo: 2024-10-04 (Japan time). Full English translation.
[U.S.] May 2024, In re Bystolic (Second Circuit Court of Appeals)
A reverse payment in a pharmaceutical patent-litigation settlement violates antitrust law if it is “large” and “unjustified.”
—Comparison with litigation costs and the value of goods and services is important.
*An issue with many occasions for consideration in Japan as well, and outside pharmaceuticals!!
Update history
The first-published date remains unchanged. Display maintenance, classification changes, related-article updates, and text corrections are recorded separately.
November 1, 2026: First published on this website.
November 2, 2026: Added article information, classification, topics, language navigation, related articles where the same case was confirmed, consultation guidance, and SEO. The original text and first-published date were preserved.
Comments